×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
XNCR – xencor, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
XNCR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/14
11:31 am
xncr
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]
Low
Report
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross [Yahoo! Finance]
11/12
05:39 am
xncr
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% [Yahoo! Finance]
Low
Report
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% [Yahoo! Finance]
11/8
11:17 am
xncr
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $34.00 price target on the stock, up previously from $32.00.
Low
Report
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at BMO Capital Markets. They now have a $34.00 price target on the stock, up previously from $32.00.
11/7
01:41 pm
xncr
Xencor, Inc. (NASDAQ: XNCR) had its price target raised by analysts at JPMorgan Chase & Co. from $27.00 to $28.00. They now have an "overweight" rating on the stock.
Low
Report
Xencor, Inc. (NASDAQ: XNCR) had its price target raised by analysts at JPMorgan Chase & Co. from $27.00 to $28.00. They now have an "overweight" rating on the stock.
11/7
11:14 am
xncr
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $38.00 price target on the stock.
Low
Report
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $38.00 price target on the stock.
11/6
04:01 pm
xncr
Xencor Reports Third Quarter 2024 Financial Results
Low
Report
Xencor Reports Third Quarter 2024 Financial Results
11/4
07:00 am
xncr
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
Low
Report
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease
11/1
11:55 am
xncr
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? [Yahoo! Finance]
Low
Report
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
06:38 pm
xncr
Form 4 Xencor Inc For: Nov 13 Filed by: Dahiyat Bassil I
Low
Report
Form 4 Xencor Inc For: Nov 13 Filed by: Dahiyat Bassil I
11/14
06:16 pm
xncr
Form SC 13G/A Xencor Inc Filed by: EcoR1 Capital, LLC
Low
Report
Form SC 13G/A Xencor Inc Filed by: EcoR1 Capital, LLC
11/14
01:24 pm
xncr
Form SC 13G/A Xencor Inc Filed by: PRICE T ROWE ASSOCIATES INC /MD/
Low
Report
Form SC 13G/A Xencor Inc Filed by: PRICE T ROWE ASSOCIATES INC /MD/
11/13
05:46 pm
xncr
Form 4 Xencor Inc For: Nov 11 Filed by: Desjarlais John R
Low
Report
Form 4 Xencor Inc For: Nov 11 Filed by: Desjarlais John R
11/13
04:22 pm
xncr
Form 144 Xencor Inc Filed by: Dahiyat Bassil I
Low
Report
Form 144 Xencor Inc Filed by: Dahiyat Bassil I
11/12
04:01 pm
xncr
Form SC 13G/A Xencor Inc Filed by: PRIMECAP MANAGEMENT CO/CA/
Low
Report
Form SC 13G/A Xencor Inc Filed by: PRIMECAP MANAGEMENT CO/CA/
11/12
09:27 am
xncr
Form 144 Xencor Inc Filed by: Desjarlais John R
Low
Report
Form 144 Xencor Inc Filed by: Desjarlais John R
11/8
02:21 pm
xncr
Form SC 13G/A Xencor Inc Filed by: BlackRock, Inc.
Low
Report
Form SC 13G/A Xencor Inc Filed by: BlackRock, Inc.
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
6/24
MarketAxess Holdings Set to Join S&P 500; Axon Enterprise to Join S&P MidCap 400; Others to Join S&P SmallCap 600
13.8%
5/9 Xencor Reports First Quarter 2019 Financial Results 10.3%
6/30 Xencor: Multiple Data Readouts In Second Half Of 2019 For This 'Picks And Shovels' Play [Seeking Alpha] 7.2%
2/5 Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments 6.1%
3/4 Xencor Inc (NASDAQ: XNCR) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $28.00 price target on the stock. 5.7%
3/25 Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19 5.3%
8/8 Xencor Inc (NASDAQ: XNCR) had its price target raised by analysts at Canaccord Genuity from $45.00 to $52.00. They now have a "buy" rating on the stock. 5.0%
3/23 Form 4 Xencor Inc For: Mar 19 Filed by: STAFFORD JOHN S III 4.7%
6/27 Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D. 3.6%
1/30 Xencor Inc (NASDAQ: XNCR) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating on the stock. 3.2%
5/9 Xencor Reports First Quarter 2019 Financial Results 10.3%
6/30 Xencor: Multiple Data Readouts In Second Half Of 2019 For This 'Picks And Shovels' Play [Seeking Alpha] 7.2%
2/5 Aimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy Treatments 6.1%
3/4 Xencor Inc (NASDAQ: XNCR) is now covered by analysts at Barclays PLC. They set an "underweight" rating and a $28.00 price target on the stock. 5.7%
3/25 Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19 5.3%
8/8 Xencor Inc (NASDAQ: XNCR) had its price target raised by analysts at Canaccord Genuity from $45.00 to $52.00. They now have a "buy" rating on the stock. 5.0%
3/23 Form 4 Xencor Inc For: Mar 19 Filed by: STAFFORD JOHN S III 4.7%
6/27 Xencor Announces the Planned Retirement of Chief Medical Officer Paul Foster, M.D. 3.6%
1/30 Xencor Inc (NASDAQ: XNCR) is now covered by analysts at Royal Bank of Canada. They set an "outperform" rating on the stock. 3.2%
TOP News Decliners
8/6
Xencor, Inc. (XNCR) CEO Bassil Dahiyat on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha]
-20.0%
2/26 Xencor Inc (NASDAQ: XNCR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.7%
1/25 Xencor Inc (NASDAQ: XNCR) had its "buy" rating re-affirmed by analysts at Zacks Investment Research. They now have a $42.00 price target on the stock. -3.9%
4/30 Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020 -4.0%
1/8 Form 4 Xencor Inc For: Jan 06 Filed by: STAFFORD JOHN S III -5.0%
8/22 Form 4 Xencor Inc For: Aug 21 Filed by: Kuch John J -5.6%
8/21 Form 4 Xencor Inc For: Aug 19 Filed by: Desjarlais John R -6.1%
4/29 Form DEF 14A Xencor Inc For: Jun 25 -6.7%
5/12 Xencor Inc (NASDAQ: XNCR) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $40.00 price target on the stock. -7.5%
12/26 Form 4 Xencor Inc For: Dec 20 Filed by: STAFFORD JOHN S III -8.4%
2/26 Xencor Inc (NASDAQ: XNCR) was downgraded by analysts at ValuEngine from a "buy" rating to a "hold" rating. -3.7%
1/25 Xencor Inc (NASDAQ: XNCR) had its "buy" rating re-affirmed by analysts at Zacks Investment Research. They now have a $42.00 price target on the stock. -3.9%
4/30 Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020 -4.0%
1/8 Form 4 Xencor Inc For: Jan 06 Filed by: STAFFORD JOHN S III -5.0%
8/22 Form 4 Xencor Inc For: Aug 21 Filed by: Kuch John J -5.6%
8/21 Form 4 Xencor Inc For: Aug 19 Filed by: Desjarlais John R -6.1%
4/29 Form DEF 14A Xencor Inc For: Jun 25 -6.7%
5/12 Xencor Inc (NASDAQ: XNCR) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $40.00 price target on the stock. -7.5%
12/26 Form 4 Xencor Inc For: Dec 20 Filed by: STAFFORD JOHN S III -8.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: